312 related articles for article (PubMed ID: 15313890)
1. SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant.
Tsavachidou D; Coleman ML; Athanasiadis G; Li S; Licht JD; Olson MF; Weber BL
Cancer Res; 2004 Aug; 64(16):5556-9. PubMed ID: 15313890
[TBL] [Abstract][Full Text] [Related]
2. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation.
Satyamoorthy K; Li G; Gerrero MR; Brose MS; Volpe P; Weber BL; Van Belle P; Elder DE; Herlyn M
Cancer Res; 2003 Feb; 63(4):756-9. PubMed ID: 12591721
[TBL] [Abstract][Full Text] [Related]
3. Suppression of BRAF(V599E) in human melanoma abrogates transformation.
Hingorani SR; Jacobetz MA; Robertson GP; Herlyn M; Tuveson DA
Cancer Res; 2003 Sep; 63(17):5198-202. PubMed ID: 14500344
[TBL] [Abstract][Full Text] [Related]
4. Microarray expression profiling in melanoma reveals a BRAF mutation signature.
Pavey S; Johansson P; Packer L; Taylor J; Stark M; Pollock PM; Walker GJ; Boyle GM; Harper U; Cozzi SJ; Hansen K; Yudt L; Schmidt C; Hersey P; Ellem KA; O'Rourke MG; Parsons PG; Meltzer P; Ringnér M; Hayward NK
Oncogene; 2004 May; 23(23):4060-7. PubMed ID: 15048078
[TBL] [Abstract][Full Text] [Related]
5. Spry2 expression correlates with BRAF mutation in thyroid cancer.
Xu L; Zhou JL; Cohen M; Bar-Sagi D; Patel KN
Surgery; 2010 Dec; 148(6):1282-7; discussion 1287. PubMed ID: 21134562
[TBL] [Abstract][Full Text] [Related]
6. Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression.
Kono M; Dunn IS; Durda PJ; Butera D; Rose LB; Haggerty TJ; Benson EM; Kurnick JT
Mol Cancer Res; 2006 Oct; 4(10):779-92. PubMed ID: 17050671
[TBL] [Abstract][Full Text] [Related]
7. Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma.
Kumar SM; Yu H; Edwards R; Chen L; Kazianis S; Brafford P; Acs G; Herlyn M; Xu X
Cancer Res; 2007 Apr; 67(7):3177-84. PubMed ID: 17409425
[TBL] [Abstract][Full Text] [Related]
8. Reduction in Raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines.
Schuierer MM; Bataille F; Hagan S; Kolch W; Bosserhoff AK
Cancer Res; 2004 Aug; 64(15):5186-92. PubMed ID: 15289323
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms.
Sutterlüty H; Mayer CE; Setinek U; Attems J; Ovtcharov S; Mikula M; Mikulits W; Micksche M; Berger W
Mol Cancer Res; 2007 May; 5(5):509-20. PubMed ID: 17510316
[TBL] [Abstract][Full Text] [Related]
10. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.
Sharma A; Trivedi NR; Zimmerman MA; Tuveson DA; Smith CD; Robertson GP
Cancer Res; 2005 Mar; 65(6):2412-21. PubMed ID: 15781657
[TBL] [Abstract][Full Text] [Related]
11. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins.
Friday BB; Yu C; Dy GK; Smith PD; Wang L; Thibodeau SN; Adjei AA
Cancer Res; 2008 Aug; 68(15):6145-53. PubMed ID: 18676837
[TBL] [Abstract][Full Text] [Related]
12. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.
Omholt K; Platz A; Kanter L; Ringborg U; Hansson J
Clin Cancer Res; 2003 Dec; 9(17):6483-8. PubMed ID: 14695152
[TBL] [Abstract][Full Text] [Related]
13. Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors.
Ikenoue T; Hikiba Y; Kanai F; Tanaka Y; Imamura J; Imamura T; Ohta M; Ijichi H; Tateishi K; Kawakami T; Aragaki J; Matsumura M; Kawabe T; Omata M
Cancer Res; 2003 Dec; 63(23):8132-7. PubMed ID: 14678966
[TBL] [Abstract][Full Text] [Related]
14. Thrombopoietin-mediated sustained activation of extracellular signal-regulated kinase in UT7-Mpl cells requires both Ras-Raf-1- and Rap1-B-Raf-dependent pathways.
Garcia J; de Gunzburg J; Eychène A; Gisselbrecht S; Porteu F
Mol Cell Biol; 2001 Apr; 21(8):2659-70. PubMed ID: 11283246
[TBL] [Abstract][Full Text] [Related]
15. ARMS depletion facilitates UV irradiation induced apoptotic cell death in melanoma.
Liao YH; Hsu SM; Huang PH
Cancer Res; 2007 Dec; 67(24):11547-56. PubMed ID: 18089783
[TBL] [Abstract][Full Text] [Related]
16. Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines.
Tanami H; Imoto I; Hirasawa A; Yuki Y; Sonoda I; Inoue J; Yasui K; Misawa-Furihata A; Kawakami Y; Inazawa J
Oncogene; 2004 Nov; 23(54):8796-804. PubMed ID: 15467732
[TBL] [Abstract][Full Text] [Related]
17. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia.
Yuen ST; Davies H; Chan TL; Ho JW; Bignell GR; Cox C; Stephens P; Edkins S; Tsui WW; Chan AS; Futreal PA; Stratton MR; Wooster R; Leung SY
Cancer Res; 2002 Nov; 62(22):6451-5. PubMed ID: 12438234
[TBL] [Abstract][Full Text] [Related]
18. In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling.
Dumaz N; Hayward R; Martin J; Ogilvie L; Hedley D; Curtin JA; Bastian BC; Springer C; Marais R
Cancer Res; 2006 Oct; 66(19):9483-91. PubMed ID: 17018604
[TBL] [Abstract][Full Text] [Related]
19. Lack of BRAF mutations in uveal melanoma.
Rimoldi D; Salvi S; Liénard D; Lejeune FJ; Speiser D; Zografos L; Cerottini JC
Cancer Res; 2003 Sep; 63(18):5712-5. PubMed ID: 14522889
[TBL] [Abstract][Full Text] [Related]
20. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.
Liu D; Hu S; Hou P; Jiang D; Condouris S; Xing M
Clin Cancer Res; 2007 Feb; 13(4):1341-9. PubMed ID: 17317846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
